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ABSTRACT 
 The inhibitory co-receptor programmed cell 
death 1 (PD-1, Pdcd1) plays critical roles in the 
regulation of autoimmunity, anti-cancer immunity, 
and immunity against infections. Immunotherapies 
targeting PD-1 have revolutionized cancer 
management and instigated various trials of 
improved cancer immunotherapies. Moreover, 
extensive trials are underway to potentiate PD-1 
function in order to suppress harmful immune 
responses. Here, we found that both natural and 
synthetic glucocorticoids (GCs) up-regulate PD-1 
on T cells without altering the expression levels of 
other co-receptors and cell-surface molecules. The 
GC-induced up-regulation of PD-1 depended on the 
transactivation of PD-1 transcription mediated 
through the glucocorticoid receptor (GR). We 
further found that a GC response element (GRE) 
2525 bp upstream from the transcription start site of 
Pdcd1 is responsible for GC-mediated 
transactivation. We also observed that in vivo 
administration of GCs significantly up-regulates 
PD-1 expression on tumor-infiltrating T cells. By 
analyzing T cells differing in PD-1 expression, we 
directly demonstrated that the amount of PD-1 on 
the cell surface correlates with its inhibitory effect. 
Accordingly, GCs potentiated the capacity of PD-1 
to inhibit T cell activation, suggesting that this PD-
1-mediated inhibition contributes, at least in part, to 
the anti-inflammatory and immunosuppressive 
effects of GCs. In light of the critical roles of PD-1 
in the regulation of autoimmunity regulation, we 
expect that the potentiation of PD-1 activity may 
offer a promising therapeutic strategy for managing 
inflammatory and autoimmune diseases. Our 
current findings provide a rationale for strategies 
seeking to enhance the inhibitory effect of PD-1 by 
increasing its expression level.  
 
 The inhibitory co-receptor programmed cell 
death 1 (PD-1) is inducibly expressed on T cells 
upon activation and inhibits T cell receptor (TCR) 
signaling by recruiting SHP-2, a protein tyrosine 
phosphatase in a manner dependent on the 
engagement by either of its two ligands, PD-L1 and 
PD-L2 (1,2). PD-1-dependent regulation of TCR 
signal is required for the establishment and the 
maintenance of immune tolerance to self and the 
suppression of excess immune responses to 
pathogens. Mice deficient for PD-1 spontaneously 
develop tissue-specific autoimmune diseases and 
die of sever inflammatory tissue damage upon 
infection with pathogens that normally establish 
chronic infection in PD-1-sufficient mice (3,4). On 
the other hand, this immunoregulatory function of 
PD-1 is often hijacked by tumors to escape from the 
cancer immune surveillance. Cancer 
immunotherapies targeting PD-1 therefore 
successfully eradicates various types of tumors by 
restoring the tumoricidal activities of tumor-
specific T cells (5,6). As anticipated from the 
autoimmune phenotypes of PD-1-deficient mice, 
targeted blockade of PD-1 activates not only tumor-
specific T cells but also self-reactive T cells to 
provoke inflammatory tissue damages termed 
immune-related adverse events (irAEs)(7,8). 
 http://www.jbc.org/cgi/doi/10.1074/jbc.RA119.010379The latest version is at 
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 Various kinds of immunosuppressants have 
been developed and widely used for the treatment 
of autoimmune diseases, allergic diseases, 
transplant rejection and so on (9). However, most 
of these drugs have a low therapeutic index and 
can cause various side effects that are dependent on 
time and dose, requiring special caution in their use. 
Although the molecular mechanisms of action of 
immunosuppressants have been extensively 
analyzed, the actual effects of immunosuppressants 
on the expression and function of immune-related 
molecules including immune-checkpoint molecules 
have not been fully understood, which makes the 
rational design of regimen with higher efficacy and 
safety difficult. 
 Among various immunosuppressants, 
glucocorticoids (GCs) have been a mainstay drug in 
the treatment of numerous inflammatory diseases 
including irAEs of cancer immunotherapies. GCs, 
a class of steroid hormones playing critical roles in 
diverse physiological processes, have profound 
anti-inflammatory and immunosuppressive 
activities (10). Pharmacological effects of GCs are 
predominantly mediated through the glucocorticoid 
receptor (GR), which is a member of the nuclear 
receptor superfamily of ligand-dependent 
transcription factors (TFs). Upon interacting with 
GC in the cytoplasm, GR translocates into the 
nucleus where it functions either as a transcriptional 
activator or repressor (11). GCs attenuate the 
expression of pro-inflammatory cytokines, induce 
apoptotic cell death, or impede the recruitment of 
immune cells by inhibiting the expression of 
adhesion molecules and chemokines in the 
suppression of inflammation (10). In T cells, GCs 
suppress T cell activation by abrogating TCR-
induced gene expression or inhibiting dendritic cell 
maturation (12-15). Despite its potent anti-
inflammatory effects, recent studies revealed that 
GCs might also augment immune reposes by up-
regulating genes involved in innate immunity 
(16,17). In addition to genomic effects, which 
involve the induction/suppression of genes, GCs 
have also been reported to function in a non-
genomic manner (18). Thus, GCs have extremely 
diverse and complicated effects on immune and 
non-immune cells, which have not been fully 
understood. 
 In this study, we found that natural and 
synthetic GCs up-regulate PD-1 on T cells by 
augmenting PD-1 transcription without changing 
the expression levels of other co-receptors. We also 
observed that in vivo administration of GCs 
significantly up-regulated PD-1 expression on 
tumor-infiltrating T cells. We identified a GC 
response element (GRE) that is responsible for the 
GC-mediated transactivation in the promoter region 
of PD-1 gene. By analyzing T cells expressing PD-
1 to a variable degree, we directly demonstrated 
that the amount of PD-1 on cell surface correlated 
with its inhibitory effect. Accordingly, GCs 
potentiated the inhibitory effect of PD-1 on the 
antigen-dependent functional T cell activation. 
These results provide new insights into the 
mechanisms underlying the immunosuppressive 
effects of GCs and provide a rationale for the 
strategy to enhance the inhibitory effect of PD-1 by 
augmenting its expression level.  
 
Results  
Dexamethasone strongly enhances PD-1 
expression on T hybridoma cells 
 A variety of drugs have been developed as 
immunosuppressants with different mechanisms of 
action. First, we assessed the effects of 
immunosuppressants on PD-1 expression using 
DO11.10 T hybridoma cells that endogenously 
express PD-1 on their surface and up-regulate PD-
1 expression upon TCR-dependent activation. 
Treatments with cyclophosphamide monohydrate 
(CPA, an alkylating agent inhibiting DNA 
synthesis) and mizoribine (MZB, an imidazole 
nucleoside inhibiting the de novo synthesis of 
guanosine) did not affect PD-1 expression levels at 
all (Fig. 1, A and B). The expression levels of PD-1 
were slightly enhanced by everolimus (ERL, a 
selective inhibitor of the serine-threonine kinase 
mammalian target of rapamycin (mTOR)) (Fig. 1, 
A and B), consistent with the previous report that 
mTOR induces T-box transcription factor (T-bet) 
that represses the transcription of PD-1 mRNA 
(18,19). High-dose cyclosporin A (CPA, a selective 
inhibitor of calcineurin) reduced PD-1 expression 
(Fig. 1, A and B), which suggests that the 
endogenous expression of PD-1 on DO11.10 T 
hybridoma cells depends on Ca2+-calcineurin-
NFAT signaling, as is the case with PD-1 expression 
upon T cell activation (20). Notably, we found that 
PD-1 expression was strongly augmented by the 
treatment with dexamethasone (Dex, a synthetic 
GC with potent anti-inflammatory activities) in 
dose- and time-dependent manners (Fig. 1, A–C). 
Although Dex also induced apoptotic cell death of 
DO11.10 T hybridoma cells in dose- and time-
dependent manners (Fig. 1, D and E; and Fig. S1), 
the augmentation of PD-1 expression was observed 
on live cells and preceded cell death, indicating that 
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effects caused by cell death. Consistently, cell death 
but not PD-1 up-regulation by Dex was canceled by 
Z-VAD-FMK, an inhibitor of apoptotic cell death 
(Fig. S1). In addition, no statistically significant 
correlation was detected between the changes in 
PD-1 expression level and viabilities of cells treated 
with immunosuppressants at various concentrations 
(Fig. S2). We also confirmed that apoptosis 
inducers do not necessarily up-regulate PD-1 
expression (Fig. S3). Collectively, PD-1 up-
regulation by Dex is likely mediated by its specific 
pharmacological action. 
  
GCs selectively enhance PD-1 expression on T 
hybridoma cells 
 In addition to Dex, various synthetic analogues 
of GC have been developed for the treatment of 
inflammatory diseases. When we examined natural 
and synthetic GCs, all GCs tested enhanced PD-1 
expression on DO11.10 T hybridoma cells to a 
similar extent as Dex. Intriguingly, expression 
levels of other cell surface molecules tested were 
not affected by Dex and hydrocortisone (HC) (Fig. 
2, A and B; and Fig. S4, A–C).  
 DO11.10 T hybridoma cells recognize 323–339 
segment of chicken ovalbumin (pOVA323−339) in the 
context of I-Ad. When we stimulated DO11.10 T 
hybridoma cells by co-culturing with pOVA323–339-
pulsed IIA1.6 B lymphoma cells expressing I-Ad, 
DO11.10 T hybridoma cells were activated to 
express or up-regulate activation markers such as 
CD69, CD28, 4-1BB, and RANKL as well as PD-1 
to a variable degree (Fig. 2C). The addition of Dex 
and HC in the co-culture attenuated the activation-
induced expression/up-regulation of most 
activation markers, which likely reflects the 
reduced levels of T cell activation by GC-treatment. 
On the other hand, the expression level of PD-1 was 
further augmented by GCs, indicating that the 
magnitude of PD-1 up-regulation by GCs 
outweighs the magnitude of PD-1 down-regulation 
due to the reduced T cell activation by GCs (Fig. 2C 
and Fig. S4D). Therefore, the augmentation of the 
expression by the treatment with GCs was highly 
specific to PD-1.  
 
GCs selectively enhance PD-1 expression on 
primary T cells 
 We next tested whether GCs also augment PD-
1 expression on primary T cells. Because naïve T 
cells do not express PD-1, we induced PD-1 
expression by stimulating naïve T cells with anti-
CD3 and anti-CD28 Abs for 16 hours. When we 
added GCs during stimulation, the expression 
levels of PD-1 were augmented both on CD4+ and 
CD8+ T cells with a clear dependency on the dose 
of GCs (Fig. 3, A and B; and Fig. S5, A and B). In 
contrast, the induction of activation markers such as 
CD25, CD44, and 4-1BB was attenuated by GCs 
(Fig. 3C). The levels of their down-regulation by 
GCs were smaller compared to those in stimulated 
DO11.10 T hybridoma cells, probably because anti-
CD3 and anti-CD28 Abs activated primary T cells 
so strongly that GCs could only partially inhibit T 
cell activation.  
 The addition of GCs for 24 hours after the 
stimulation also resulted in the augmentation of 
PD-1 expression both on CD4+ and CD8+ T cells 
(Fig. 3, D and E; and Fig. S5, C and D). As is the 
case with un-stimulated DO11.10 T hybridoma 
cells, Dex and HC did not substantially affect the 
expression levels of most cell surface molecules on 
pre-activated CD8+ T cells (Fig. 3F and Fig. S5E). 
These results indicate that GCs selectively up-
regulate PD-1 on primary T cells as well. 
 
In vivo treatment with GC up-regulates PD-1 
expression on tumor-infiltrating CD8+ T cells 
 GCs are commonly used to mitigate irAEs in 
cancer patients receiving immunotherapies 
targeting PD-1 and CTLA-4 (8). To investigate the 
effect of GCs on PD-1 expression in the tumor 
setting, we analyzed PD-1 expression on T cells 
infiltrating into tumors of CT26 mouse colon 
carcinoma cells. As is well known, tumor-
infiltrating CD4+ and CD8+ T cells expressed PD-1 
at substantial levels (Fig. 4A). Notably, the 
administration of Dex significantly increased the 
expression levels of PD-1 as well as the proportion 
of PD-1 expressing cells among tumor-infiltrating 
CD8+ T cells compared with control mice treated 
with the solvent, DMSO (Fig. 4, A–C). Although 
not statistically significant, tumor-infiltrating CD4+ 
T cells also exhibited a tendency toward increased 
levels of PD-1 expression upon Dex treatment (Fig. 
4, A–C). These results indicate that GCs have a 
potential to up-regulate PD-1 expression in vivo. 
 
GC-GR complex up-regulates PD-1 mRNA by 
binding to a GRE in the promoter region  
 We tested the involvement of GR in the up-
regulation of PD-1 and cell death by GCs using 
RU486, GR antagonist. The up-regulation of PD-1 
as well as cell death by Dex was canceled by the 
addition of RU486, indicating that the up-
regulation of PD-1 and cell death by GCs are 
mediated through GR (Fig. 5A). Then we examined 
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level. The amount of PD-1 mRNA was increased 
about 2 folds by 1 hour after the addition of GCs 
and further augmented over time, which was 
canceled by RU486 (Fig. 5B and C). These results 
indicate that GCs augment PD-1 expression at the 
mRNA level through the binding to GR.  
 Then, we investigated whether the GR-GC 
complex directly increases the transcription of PD-
1 gene. By using the TF binding site prediction 
database, we identified three putative GREs at 
2,525, 2,740, and 2,790 bp upstream from the 
transcription start site of PD-1 mRNA and termed 
them as GRE1, 2, and 3, respectively. To examine 
whether the augmentation of PD-1 expression by 
GCs was mediated through these GREs, we 
generated a series of reporter constructs containing 
intact or mutated GREs. Dex-treatment strongly 
augmented the promoter activity in the presence of 
GRE1, suggesting that GRE1 is responsible for the 
augmentation of PD-1 expression by GCs (Fig. 5D).  
 
GCs potentiate the inhibitory effect of PD-1 by 
increasing the cell surface amount of PD-1  
 Upon antigen stimulation, DO11.10 T 
hybridoma cells secrete IL-2 in a manner dependent 
on the amount of antigen. Thus, we can evaluate the 
magnitude of functional T cell activation based on 
the amount of secreted IL-2. As reported previously, 
IL-2 production from DO11.10 T hybridoma cells 
upon antigen stimulation was strongly inhibited 
when IIA1.6 cells overexpressing PD-L1 (IIA1.6-
PD-L1 cells) were used as antigen presenting cells 
(APCs) and the inhibitory effect of PD-1 was 
completely canceled by anti-PD-L1 blocking Ab 
(21,22). The PD-L1-mediated inhibition was 
abolished by the targeted deletion of PD-1 gene in 
DO11.10 T hybridoma cells and restored by the 
retroviral reconstitution of PD-1 (Fig. 6, A and B). 
By using this system, we examined the correlation 
between the cell surface amount of PD-1 and its 
inhibitory effect. We overexpressed PD-1 at various 
levels by using five different promoters (EF1a, 
CMV, CAG, MC1, SV40) with or without a 
polyadenylation (pA) signal, which plays essential 
roles in the stabilization of mRNA (Fig. 6, C and D). 
These cells were stimulated with pOVA323−339-
pulsed IIA1.6-PD-L1 cells, and PD-1-mediated 
inhibitory effects were calculated by comparing the 
amount of secreted IL-2 in the presence or absence 
of anti-PD-L1 blocking Ab. We observed a strong 
positive correlation of the cell surface expression 
level of PD-1 with its inhibitory effect (Fig. 6E).  
 Then, we evaluated the functional consequence 
of PD-1 up-regulation by GCs. DO11.10 T 
hybridoma cells were treated with Dex and live 
cells were stimulated with pOVA323−339. As 
anticipated from the immunosuppressive activity of 
GCs, the pre-treatment with Dex substantially 
reduced the amount of IL-2 secreted from DO11.10 
T hybridoma cells upon antigen stimulation. PD-1 
engagement further reduced the IL-2 production 
from activated DO11.10 T hybridoma cells. 
Intriguingly, when we compared the levels of PD-
1-dependent inhibition with or without Dex pre-
treatment, PD-1 inhibited IL-2 production more 
efficiently when DO11.10 T hybridoma cells were 
pre-treated with Dex (Fig. 6, F and G). Thus, GCs 
can potentiate the inhibitory effect of PD-1 by 
increasing the cell surface amount of PD-1. 
 
No substantial effect of GCs on ectopic PD-1  
 In order to confirm the specificity of PD-1 up-
regulation by GCs, we evaluated the effect of GCs 
on ectopic PD-1. We treated DO11.10 T hybridoma 
cells that express exogenous PD-1 under LTR 
promoter but lack endogenous PD-1 expression 
with GCs. As expected, GCs failed to augment the 
cell surface amount of ectopic PD-1 (Fig.S6A). 
Accordingly, GCs failed to potentiate the inhibitory 
effect of ectopic PD-1 (Fig. S6, B and C). These 
results strongly suggest that GC-GR complex 
transactivates PD-1 transcription by directly 




 GCs have been widely used as anti-
inflammatory and immunosuppressive agents for 
the treatment of a variety of inflammatory and 
autoimmune diseases. However, despite extensive 
clinical and experimental studies, the extremely 
diverse and complicated effects of GCs on immune 
and non-immune cells have not been fully 
understood. In the current study, we found that GCs 
augment the expression level of PD-1 on T cells but 
not other cell surface molecules including CD25, 
CD44, CD69, 4-1BB, RANKL, and LAG-3. Dex 
has been reported to enhance the expression of PD-
1 and CTLA-4 on T cells, but the underlying 
mechanism and the functional consequence of the 
up-regulation were largely unknown (23-25). We 
revealed that the treatment with GCs leads to the 
transactivation of PD-1 expression in a manner 
dependent on GR and GRE in the promoter region 
of PD-1 gene. We directly demonstrated that the 
amount of PD-1 on cell surface strongly correlated 
with its inhibitory effect. Accordingly, augmented 
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enhancement of the inhibitory effects of PD-1 
against the antigen-dependent functional T cell 
activation. These findings suggest that PD-1-
mediated inhibition contributes, at least in part, to 
the anti-inflammatory and immunosuppressive 
effects of GCs. 
 Naïve T cells do not express PD-1 but rapidly 
express PD-1 upon antigen stimulation. This initial 
induction of PD-1 is driven by multiple TFs 
including nuclear factor of activated T cells 1 
(NFATc1) and c-Fos/activator protein-1 (AP-1), 
which are activated by signaling through TCR or 
Notch (20,26,27). In the setting of chronic viral 
infections and tumors, chronic antigen exposure 
induces high and sustained expression of PD-1 on 
CD8+ T cells, resulting in their functional 
exhaustion (4,28). Forkhead box protein O1 
(FoxO1), NFATc1, and nuclear receptor subfamily 
4 group A (NR4A) have been reported to mediate 
the expression of PD-1 on exhausted CD8+ T cells 
(29-32). While these TFs function as transcriptional 
activators in PD-1 expression, T-bet and Blimp-1 
have been reported to function as transcriptional 
repressors in PD-1 expression (19,33). These TFs 
cooperatively or competitively regulate PD-1 
expression by directly binding to the promoter 
region of PD-1 gene. GRs are known to exert a 
diverse function by binding to promoter sequences 
together with other TFs or by physically interacting 
with other TFs (11). In the present study, we 
identified a GRE in the promoter region of PD-1 
gene that is responsible for the transactivation by 
GC-treatment. Therefore, it is likely that GR 
directly binds to the promoter region of PD-1 gene 
in response to GC-treatment and acts as a 
transcriptional activator to augment PD-1 
transcription. Further studies are expected to reveal 
a possible positive or negative cooperation of GC-
GR complex with other TFs in the regulation of PD-
1 expression. 
 Endogenous GCs (cortisol in humans and 
corticosterone in mice) play critical roles in the 
regulation of various physiological and 
developmental processes. It was recently reported 
that endogenous GCs produced upon infection with 
mouse cytomegalovirus induced PD-1 expression 
on natural killer (NK) cells to restrain IFN-g 
production from NK cells leading to the prevention 
of immunopathology (34). Another recent study 
showed that the deletion of GR in regulatory T cells 
(Tregs) resulted in the reduction of PD-1-
expressing Tregs in spleen (35). These findings 
suggest that PD-1 expression is positively 
modulated by endogenous GCs. It is possible that 
the GRE found in the current study also mediates 
the expression of PD-1 on NK cells and Tregs by 
endogenous GCs under physiological and 
pathological conditions. 
 Because of the recent success of cancer 
immunotherapy targeting PD-1 and CTLA-4, many 
other inhibitory co-receptors are extensively 
investigated aiming to develop new cancer 
immunotherapies with higher efficacy. Revisiting 
the significance of inhibitory co-receptors in 
maintaining immunotolerance to self and 
preventing excess immune responses, the 
potentiation of their activities is expected to be a 
promising therapeutic strategy for inflammatory 
and autoimmune diseases. Our current findings 
clearly demonstrated that the expression level of 
PD-1 strongly correlated with its inhibitory 
function just like LAG-3, another inhibitory co-
receptor (36). These results provide a rationale for 
the strategy to treat inflammatory and autoimmune 
diseases by augmenting the expression levels of 




 Immunosuppressants, natural and synthetic 
glucocorticoidsused, inhibitors of cell death, and 
apoptosis inducers used in this study are as follows: 
cyclosporin A (CyA, CAS No. 1202.635, Tokyo 
Chemical Industry), cyclophosphamide 
monohydrate (CPA, CAS No. 6055-19-2, Tokyo 
Chemical Industry), mizoribine (MZR, CAS No. 
50924-49-7, Tokyo Chemical Industry), everolimus 
(ERL, CAS No. 159351-69-6, Selleck Chemicals), 
dexamethasone (Dex, CAS No. 50-02-2, Cayman 
Chemical), hydrocortisone (CAS No. 50-23-7, 
Sigma-Aldrich), prednisolone (CAS No. 50-24-8, 
Tokyo Chemical Industry), bethamethasone 
valerate (CAS No. 2152-44-5, LKT Laboratories), 
fluocinolone acetonide (CAS No. 67-73-2, Tokyo 
Chemical Industry), hydrocortisone 17-Butyrate 
(CAS No. 25122-46-7, Tokyo Chemical Industry), 
budesonide (CAS No. 51333-22-3, Tokyo 
Chemical Industry), Z-VAD-FMK (CAS No. 
187389-52-2, AdooQ Bioscience), necrostatin-1 
(CAS No. 4311-88-0, Selleck Chemicals), IM-54 
(CAS No. 861891-50-1, Cayman Chemical), 
necrosulfonamide (CAS No. 1360614-48-7, 
Cayman Chemical), cisplatin (CDDP, CAS No. 
15663-27-1, Tokyo Chemical Industry), 
camptothecin (CPT, CAS No. 7689-03-4, Tokyo 
Chemical Industry), etoposide (ETO, CAS No. 
33419-42-0, Tokyo Chemical Industry), and 
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Sigma-Aldrich). Glucocorticoid receptor 
antagonist, RU486 (Mifepristone, CAS No. 84371-
65-3) was purchased from Cayman Chemical. 
These reagents were dissolved in dimethyl 
sulfoxide (DMSO, Wako). 
 
Cell culture 
 DO11.10 mouse hybridoma T cells and CT26 
mouse colon carcinoma cells were kindly provided 
by Tasuku Honjo (Kyoto University). IIA1.6 mouse 
B lymphoma cells were kindly provided by 
Tomohiro Kurosaki (Osaka University). PD-1 
knock-out DO11.10 T hybridoma cells were 
generated by using CRISPR/Cas9 system (37). 
These cell lines were maintained in RMPI 1640 
medium (Gibco), supplemented with 10% (v/v) 
fetal bovine serum (FBS, Biowest), 0.5 mM 
Monothioglycerol (Wako), 2 mM L-alanyl-L-
glutamine dipeptide (Gibco), 100 U/ml penicillin 
(Nacalai Tesque), and 100 µg/ml streptomycin 
(Nacalai Tesque). Plat-E cells, which were kindly 
provided by Toshio Kitamura (University of Tokyo), 
were maintained in Dulbecco's Modified Eagle 
Medium (D’MEM, Gibco), supplemented with 
10% (v/v) FBS, 100 U/ml penicillin, and 100 µg/ml 
streptomycin. 
 
Plasmid and retroviral gene transduction 
 Fragments of cDNA were amplified by PCR 
and cloned into retroviral expression plasmid 
vectors modified from pFB-ires-neo (Agilent). For 
controlling the expression levels of PD-1, 
fragments of cDNA were cloned into retroviral 
expression plasmid vectors modified from 
pSUPER.retro.puro (Oligoengine), the promoter 
region of which was replaced with promoters of EF-
1a (human elongation factor-1 alpha), CMV 
(cytomegalovirus), CAG (cytomegalovirus 
enhancer/chicken beta-actin), MC1 (polyoma virus 
enhancer/herpes simplex virus thymidine kinase), 
SV40 (simian virus 40) coupled with or without a 
poly(A) signal. Plasmids were transfected using the 
FuGENE HD (Promega) into Plat-E cells cultured 
in D’MEM, high glucose (Gibco) supplemented 
with 20% (v/v) FBS, 100 U/ml penicillin, and 100 
μg/ml streptomycin, and supernatants containing 
viruses were used to transduce genes into target 
cells. Infected cells were selected with G418 




 C57BL/6J and BALB/c mice were obtained 
from Charles River Laboratories Japan and Japan 
SLC, respectively, and housed under specific 
pathogen-free conditions in environmentally 
controlled clean rooms. All experimental 
procedures were planed and conducted according to 
the institutional regulations complying with the Act 
on Welfare and Management of Animals and the 
related guidelines in Japan. All mouse protocols 
were approved by the Animal Experimentation 
Committee of Tokushima University. 
 
Stimulation of DO11.10 T hybridoma cells and 
primary T cells 
 DO11.10 T hybridoma cells (5 × 104 cells/well) 
were stimulated with IIA1.6 cells (1 × 104 
cells/well) in the presence of antigenic peptide 
(323–339 segment of chicken ovalbumin, pOVA323–
339, ISQAVHAAHAEINEAGR, >95% purity, 
eurofins) in 96-well round bottom plate (BD 
Bioscinences) for 24 hours. Where indicated, 1 
μg/ml of anti-PD-L1 blocking Ab (1-111A) or rat 
IgG2a isotype control Ig (2A3, Bio X Cell) were 
added. Activated primary T cells were prepared by 
stimulating splenocytes from C57BL/6J mice with 
soluble anti-CD3e (0.5–1 µg/ml, 145-2C-11, 
BioLegend) and anti-CD28 (0.5–1 µg/ml, 37.51, 
BioLegend) Abs. The concentration of IL-2 in the 
culture supernatant was determined by ELISA 
(BioLegend). The percent PD-1-mediated 
inhibition of IL-2 production was calculated as the 
ratio of IL-2 concentration in the presence to 
absence of anti-PD-L1 blocking Ab (1-111A). IL-2 
concentrations with different amounts of antigens 
were summed up for the calculation of the percent 
PD-1-mediated inhibition. 
 
Antibody and flowcytometric analysis 
 Cultured cell lines and primary cells were 
stained with the indicated Abs. Data were obtained 
with Gallios (Beckman Coulter) and analyzed using 
FlowJo (Tree Star). CF633-Dye-labeled anti-mouse 
LAG-3 Ab (TKB58) was prepared as described 
previously (38). All the other Abs used in this study 
were purchased from BioLegend: anti-mouse PD-1 
(RMP1-30), TCR-b (H57-597), CD3e (145-2C-11), 
CD44 (IM7), CD45 (30-F11), Thy1.2 (53-2.1), 
CD69 (H1.2F3), CD28 (37.51), 4-1BB (17B5), 
RANKL (IL22/5), CD25 (7D4), CD4 (RM4-5), and 
CD8a (53-6.7). Apoptotic cells were detected by 
using Annexin V (BioLegend). 
 
Real-time quantitative PCR 
 Total RNA was extracted from cells using 
TRIzol reagent (Ambion), and then subjected to 
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Reverse Transcription Kit (Applied Biosystems). 
Gene expression was analyzed by quantitative PCR 
using Power SYBR Green PCR Master Mix 
(Applied Biosystems) on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems). Values were 
normalized to the expression of Gapdh. The 
following specific primer sets were used: Gapdh, F 
(5′ - TTCACCACCATGGAGAAGGC - 3′) and R 
(5′ - GGCATGGACTGTGGTCATGA - 3′); Pdcd1, 
F (5′ - ACCCTGGTCATTCACTTGGG - 3′) and R 
(5′ - CATTTGCTCCCTCTGACACTG - 3′). 
 
Reporter assay 
 Putative GREs in the promoter region of PD-1 
gene were predicted by using the JASPAR database 
(39) and genomatix genome analyzer (Genomatix). 
A DNA fragment containing GRE1, GRE2, and 
GRE3 (2,790 to 2,339 bp upstream of the 
transcription start of PD-1 mRNA) was amplified 
from C57BL/6N Mouse BRC clone (B6Ng01-
240G08, RIKEN BRC) by PCR and cloned into a 
retroviral expression plasmid vector modified from 
pSUPER.retro.puro. together with a synthetic 
minimal promoter sequence and EGFP cDNA. 
Where indicated, GRE sequences 
(AGAACAnnnTGTTCT) were mutated by over-
hang PCR to AGGTCAnnnTGACCT. Reporter 
constructs were retrovirally introduced into 
DO11.10 T hybridoma cells overexpressing mouse 
GR. After selection with puromycin, cells were 
cultured in the presence of Dex (100 nM), phorbol 
12-myristate 13-acetate (PMA, 50 ng/ml, Sigma-
Aldrich), and ionomycin (500 ng/ml, Sigma-
Aldrich) for 24 hours and analyzed by flow 
cytometry. 
 
Preparation of tumor-infiltrating T cells 
 Male and female BALB/c mice (8–10 weeks 
old) were inoculated subcutaneously with 1×106 
CT26 murine colon carcinoma cells at shaved back. 
On days 10 and 12, Dex (400 µg) in 50% 
DMSO/PBS was subcutaneously injected near the 
site of tumor inoculation. On day 13, tumor tissues 
were dissected and mechanically dissociated by 
using gentleMACS Octo Dissociator with Heaters 
(Miltenyi Biotec) in RPMI 1640 containing 
Collagenase (1 mg/ml, Wako), Hyaluronidase (50 
µg/ml, Sigma-Aldrich), and DNase I (10 µg/ml, 
Sigma-Aldrich). Single cell suspensions prepared 
from tumor tissues were used for the flow 
cytometric analysis.  
 
Statistical analysis 
 Two-way ANOVA with Dunnett's and 
Bonferroni's multiple comparisons test, one-way 
ANOVA with Dunnett's multiple comparisons test, 
Pearson's correlation test, and two-tailed Student’s 
t-test was used to evaluate statistical significance. p 
< 0.05 was considered statistically significant. 
These statistical analyses were performed using 
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Figure 1. Effects of immunosuppressants on PD-1 expression. A, Surface PD-1 expression levels on 
DO11.10 T hybridoma cells after treatments with immunosuppressants. Representative histogram plots are 
shown for cells treated with indicated immunosuppressants (100 nM). Gray shaded histograms represent 
isotype control Ig staining. B–E, Dose- and time-dependent effects of immunosuppressants on PD-1 
expression (B, C) and cell viability (D, E). DO11.10 T hybridoma cells were cultured in the presence of 
indicated immunosuppressants at indicated doses (B, D) for 24 hours or Dex (100 nM, C, E) for indicated 
hours and analyzed by flow cytometry. Fold changes in PD-1 expression relative to DMSO-treated cells 
(the relative geometric mean fluorescent intensity, geoMFI of PD-1) (B, C) and the percentages of live 
(propidium iodide (PI)-negative) cells are shown (D, E). Representative plots of three independent 
experiments (A) or the mean ± s.d. of three independent experiments (B–E) are shown. Two-way ANOVA 
with Dunnett's multiple comparisons test (compared to DMSO-treated cells) (B, D) or with Bonferroni's 
multiple comparisons test (compared to DMSO-treated cells) (E). One-way ANOVA with Dunnett's 
multiple comparisons test (compared to before treatment) (C). *p < 0.05, ***p < 0.001. CyA, cyclosporin 





























































Figure 2. Selective up-regulation of PD-1 expression on T hybridoma cells by GCs. A, Surface PD-1 
expression levels on DO11.10 T hybridoma cells after treatments with GCs. Cells were treated with 
indicated GCs (100 nM) for 24 hours and their PD-1 expression level was analyzed by flow cytometry. B, 
Expression levels of cell surface molecules on DO11.10 T hybridoma cells after Dex-treatment. Cells were 
treated with Dex (100 nM) for 24 hours and the expression levels of indicated molecules were analyzed by 
flow cytometry. C, Expression of cell surface molecules on DO11.10 T hybridoma cells after antigenic 
stimulation in the presence of Dex. DO11.10 T hybridoma cells were stimulated by co-culturing with 
pOVA323–339-pulsed IIA1.6 cells for 24 hours in the presence Dex (100 nM) and the expression of indicated 
molecules on live DO11.10 T hybridoma cells (PI–B220–TCR-b+) cells were analyzed by flow cytometry. 
Representative histogram plots and the mean ± s.d. of three independent experiments are shown (A–C). 
Gray shaded histograms represent isotype control Ig staining (A–C). One-way ANOVA with Dunnett's 
multiple comparisons test (compared to DMSO-treated cells) (A) and with Tukey's multiple comparisons 






































































Figure 3. Selective up-regulation of PD-1 expression on primary T cells by GCs. A–C, Expression levels 
of PD-1 (A, B) and cell surface molecules (C) on primary T cells stimulated with anti-CD3e/CD28 Abs in 
the presence of Dex. Splenocytes from C57BL/6J mice were cultured in the presence of soluble anti-CD3e 
Ab, anti-CD28 Ab, and Dex for 16 hours and analyzed by flow cytometry. D–F, Effects of Dex on the 
expression of PD-1 (D, E) and cell surface molecules (F) of pre-activated primary T cells. Splenocytes from 
C57BL/6J mice were pre-activated with soluble anti-CD3e and anti-CD28 Abs for 48 h. The pre-activated 
cells were cultured in the presence of Dex for 24 hours and analyzed by flow cytometry. Representative 
histogram plots of cells treated with Dex (1 µM) and changes in the expression levels of indicated molecules 
are shown for CD4+ (gated on PI–TCR-β+CD4+ cells) (A), CD8+ (gated on PI–TCR-β+CD8+ cells) (B, C), 
pre-activated CD4+ (D), and pre-activated CD8+ (E, F) T cells. Gray shaded histograms represent isotype 
control Ig staining (A–F). Data indicates the mean ± s.d. of biological triplicates in one representative 
experiment (A–F). Data are representative of at least two independent experiments (A–F). One-way 
ANOVA with Dunnett's multiple comparisons test (compared to DMSO-treated cells) (A–F). *p < 0.05, 


















































Figure 4. Up-regulation of PD-1 on tumor-infiltrating CD8+ T cells by GCs. A–C, Surface PD-1 
expression levels on T cells infiltrating in tumors of CT26 colon carcinoma cells. BALB/c mice were 
administered subcutaneously with DMSO or Dex (400 µg) at 10 and 12 days after the subcutaneous 
inoculation of CT26 cells. At day 13, the percentages of tumor-infiltrating CD4+ and CD8+ T cells 
expressing PD-1 (gated on PI–CD45+CD4+ and PI–CD45+ CD8+, respectively) (A, B) and the expression 
levels of PD-1 on PD-1-expressing CD4+ and CD8+ T cells (geoMFI, C) were analyzed by flow cytometry. 
Representative histogram plots of three independent experiments are shown (A). Each symbol represents 
an individual mouse (n = 10, each) and horizontal lines denote the mean ± s.e.m. of ten biological replicates 
























































Figure 5. GR-dependent augmentation of PD-1 transcription by GC-treatment. A, Abrogation of GC-
mediated PD-1 up-regulation and cell death by glucocorticoid receptor antagonist, RU486. DO11.10 T 
hybridoma cells were cultured in the presence of Dex (100 nM) and RU486 (10 µM) for 24 hours and 
analyzed by flow cytometry. Fold changes in PD-1 expression relative to DMSO-treated cells and the 
percentages of live cells are shown. Gray shaded histograms represent isotype control Ig staining. B, The 
time-course of PD-1 mRNA expression in DO11.10 T hybridoma cells after treatment with Dex. Expression 
levels of PD-1 mRNA were determined by real-time quantitative PCR and normalized to those of GAPDH 
mRNA. Fold changes relative to DMSO-treated cells are shown. C, Abrogation of GC-mediated PD-1 
mRNA up-regulation by RU486. DO11.10 T hybridoma cells were cultured in the presence of Dex (100 
nM) and RU486 (10 µM) for 24 hours and fold changes of PD-1 mRNA expression relative to DMSO-
treated cells were determined as in (B). D, Promoter activity of DNA sequences containing three putative 
GREs in the promoter region of PD-1 upon GC-treatment. Schematic representations of reporter constructs 
encoding EGFP cDNA and the promoter region of PD-1 (2,790 to 2,339 bp upstream from the transcription 
start site) with or without amino acid mutations in the putative GREs (left). DO11.10 T hybridoma cells 
transduced with mouse GR and indicated reporter constructs were cultured in the presence of Dex (100 
nM), PMA (50 ng/ml), and ionomycin (500 ng/ml) for 24 hours, and analyzed by flow cytometry. Relative 
geoMFIs of EGFP compared to DMSO-treated cells are shown. The mean ± s.d. (A, C) or s.e.m (D) of 
three independent experiments or the mean ± s.d. of technical triplicates in one out of three independent 
experiments (B) are shown. One-way ANOVA with Dunnett's multiple comparisons test compared to 
DMSO-treated cells (A–C) or cells with wild type (WT) reporter construct (D). *p < 0.05, **p < 0.01, ***p 






























































Figure 6. Potentiation of the inhibitory effect of PD-1 by GCs. A, Surface PD-1 expression levels on 
DO11.10 T hybridoma cells with or without deletion and overexpression of PD-1. B, Restoration of PD-1-
mediaeted inhibitory effects by overexpression of PD-1 in DO11.10 T hybridoma cells with targeted 
deletion of PD-1 gene. IL-2 concentration in the culture supernatant is shown for indicated DO11.10 T 
hybridoma cells stimulated with pOVA323−339-pulsed IIA1.6-PD-L1 cells in the presence or absence of anti-
PD-L1 blocking Ab for 24 hours. C, Schematic representations of retroviral expression vectors. Mouse PD-
1 cDNA was overexpressed in DO11.10 T hybridoma cells with targeted deletion of PD-1 gene using 
indicated promoters with or without polyA signal. D, Flow cytometric analysis of DO11.10 T hybridoma 
cells overexpressing PD-1 at various levels by using retroviral expression vectors shown in (C). E, The 
correlation between the percent inhibition of IL-2 production by PD-1 and the expression level of PD-1 
(MFI). DO11.10 T hybridoma cells with different PD-1 expression levels were stimulated as in (B). r, 
Pearson's correlation coefficient. F and G, Augmentation of PD-1-mediated inhibitory effects by Dex. 
DO11.10 T hybridoma cells were treated with Dex (100 nM) or DMSO for 24 hours and rested for 6 hours. 
The same number of Dex- or DMSO-treated live cells was stimulated for 24 hours as in (B). IL-2 
concentration in the culture supernatant (F) and the percent inhibition of IL-2 production by PD-1 (G) are 
shown. Data are the mean ± s.d. of technical duplicates in one representative experiment (B, F) or the mean 
± s.d. of four independent experiments (G). Data are representative of at least three independent experiments 
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